Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit.

Padrnos L, Bennett R, Kosiorek H, Dueck AC, Northfelt D, Mikhael J, Tibes R, Khera N, Mesa RA.

J Cancer Educ. 2016 Oct 11. [Epub ahead of print]

PMID:
27730534
2.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, Shapiro GI.

J Clin Oncol. 2016 Sep 6. pii: JCO675991. [Epub ahead of print]

PMID:
27601554
3.

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

Ravandi F, Gojo I, Patnaik MM, Minden MD, Kantarjian H, Johnson-Levonas AO, Fancourt C, Lam R, Jones MB, Knox CD, Rose S, Patel PS, Tibes R.

Leuk Res. 2016 Sep;48:92-100. doi: 10.1016/j.leukres.2016.07.004.

PMID:
27544076
4.

Sonidegib phosphate: new approval for basal cell carcinoma.

Tibes R.

Drugs Today (Barc). 2016 May;52(5):295-303. doi: 10.1358/dot.2016.52.5.2470697.

PMID:
27376162
5.

A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome.

Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R.

Leuk Lymphoma. 2016 Nov;57(11):2535-40. doi: 10.3109/10428194.2016.1173213.

PMID:
27122296
6.

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.

Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK.

Blood Cancer J. 2016 Feb 26;6:e397. doi: 10.1038/bcj.2016.1.

7.

Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.

Tiedemann RL, Hlady RA, Hanavan PD, Lake DF, Tibes R, Lee JH, Choi JH, Ho TH, Robertson KD.

Oncotarget. 2016 Jan 12;7(2):1927-46. doi: 10.18632/oncotarget.6481.

8.

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA, Bogenberger JM.

J Hematol Oncol. 2015 Oct 20;8:114. doi: 10.1186/s13045-015-0211-8.

9.

Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy.

Finn L, Sproat L, Heckman MG, Jiang L, Diehl NN, Ketterling R, Tibes R, Valdez R, Foran J.

Cancer Epidemiol. 2015 Dec;39(6):1084-92. doi: 10.1016/j.canep.2015.09.003.

PMID:
26365691
10.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

11.

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.

Lancet Oncol. 2015 Sep;16(9):1099-110. doi: 10.1016/S1470-2045(15)00038-8.

PMID:
26296954
12.

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.

Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP.

PLoS One. 2015 Jul 16;10(7):e0132831. doi: 10.1371/journal.pone.0132831.

13.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.

Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE.

Haematologica. 2015 Sep;100(9):1172-9. doi: 10.3324/haematol.2015.125849.

14.

Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.

Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O'Neill BP.

Clin Cancer Res. 2015 Sep 1;21(17):3986-94. doi: 10.1158/1078-0432.CCR-14-2116.

15.

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Garcia-Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight EA, Xiong H, Qin Q, Munasinghe W, Roberts-Rapp L, Ansell P, Albert DH, Oliver B, McKee MD, Ricker JL, Khoury HJ.

Invest New Drugs. 2015 Aug;33(4):870-80. doi: 10.1007/s10637-015-0242-6.

PMID:
25933833
16.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MDS/MPN International Working Group..

Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341.

17.

Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Tibes R, McDonagh KT, Lekakis L, Bogenberger JM, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R, Schroeder K, Shanmugam V, Carpten J, Hagelstrom RT, Beaudry C, Von Hoff D, Shea TC.

Invest New Drugs. 2015 Apr;33(2):389-96. doi: 10.1007/s10637-014-0198-y.

PMID:
25523151
18.

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM Jr, Von Hoff DD, Burris HA 3rd, Orlemans EO, Ramanathan RK.

Eur J Cancer. 2014 Nov;50(17):2897-904. doi: 10.1016/j.ejca.2014.07.017.

PMID:
25262379
19.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.

Br J Cancer. 2014 Jul 15;111(2):272-80. doi: 10.1038/bjc.2014.290.

20.

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM.

Haematologica. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. Review. No abstract available.

Items per page

Supplemental Content

Support Center